Elagolix

Drug Profile

Elagolix

Alternative Names: ABT-620; Elagolix sodium; NBI-56418

Latest Information Update: 15 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Icahn School of Medicine at Mount Sinai
  • Developer AbbVie; Neurocrine Biosciences
  • Class Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules
  • Mechanism of Action LHRH receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometriosis; Uterine leiomyoma
  • Discontinued Benign prostatic hyperplasia; Prostate cancer

Most Recent Events

  • 07 Jul 2017 Phase-III clinical trials in Endometriosis (Combination therapy) in USA (PO) (NCT03213457)
  • 23 May 2017 Abbvie completes a phase III extension trial in Endometriosis in USA, Argentina, Australia, Austria, Brazil, New Zealand, South Africa, United Kingdom, Italy, Austria, the Czech Republic, Hungary, Poland and Spain(NCT02143713)
  • 09 May 2017 Neurocrine Biosciences announces intention to submit NDA with the US FDA for Uterine leiomyoma in USA in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top